Hip and knee implants are a big market -- according to Smith & Nephew's (NYSE:SNN) 2013 annual report, worth $14 billion last year. And given that the market has seen strong growth, with Medicare-covered knee replacement surgeries growing by 162% from 1991 to 2010, it's time to consider what investments might be most attractive in this market -- particularly given that most of them pay a dividend. So, Smith & Nephew? Zimmer (NYSE:ZMH)? Stryker (NYSE:SYK)? Johnson & Johnson (NYSE:JNJ)?

In the video below, Motley Fool health care analysts Michael Douglass and David Williamson give their take. 

Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That’s beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor’s portfolio. To see our free report on these stocks, just click here now.

David Williamson owns shares of Johnson & Johnson. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson and Zimmer Holdings. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Compare Brokers